Heidelberg Pharma Reduces Costs and Focuses on HDP-101 Amid Payment Delay

Heidelberg Pharma AG has announced significant cost-cutting measures, including a 75% reduction in workforce, after a USD 70 million milestone payment was delayed. Despite this, the company will continue its clinical Phase I/IIa trial of HDP-101 for multiple myeloma. HDP-102's clinical program is paused, while HDP-103's submission is on schedule.

The company aims to extend its cash reach until mid-2026 by focusing solely on its lead candidate, HDP-101. Other pipeline programs are subject to adaptation, and early research activities will be gradually discontinued. Heidelberg Pharma is exploring outlicensing options for preclinical programs and evaluating alternative financing avenues to ensure operational continuity.